GLPwatch
Bydureon for Obesity
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for obesity, and any use for this condition is off-label or investigational. The listed research shows that exenatide has been studied for weight loss and metabolic effects in various populations, including those with obesity, type 2 diabetes, and other conditions.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Obesity |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Bydureon is not FDA-approved for obesity; the research below reflects investigational or off-label study only.
Research on exenatide for obesity (50)
- DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
- Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
- Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
- Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.
- Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.
- Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
- Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
- GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice.
- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
- Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
- A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
- Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
- Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
- Exenatide therapy in insulin-treated type 2 diabetes and obesity.
- Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.